CRISPR THERAPEUTICS AG
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $291.3M | $423.3M | $347.6M | $286.5M | $193.6M | $235.2M | $298.3M | $225.7M |
| Accounts Receivable | — | — | $0 | $0 | $0 | $0 | $25.0M | $0 |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B |
| Property, Plant & Equipment | $108.1M | $112.2M | $115.9M | $120.8M | $124.9M | $129.4M | $134.1M | $138.5M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | $0 | $0 |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B |
| Liabilities | ||||||||
| Accounts Payable | $11.3M | $13.6M | $11.1M | $11.8M | $9.8M | $13.1M | $14.7M | $15.6M |
| Total Current Liabilities | $132.9M | $136.3M | $149.1M | $119.0M | $104.4M | $119.4M | $87.8M | $89.8M |
| Long-Term Debt | $586.2M | $585.5M | $0 | — | — | — | — | — |
| Total Liabilities | $904.2M | $911.3M | $343.4M | $329.3M | $318.6M | $336.9M | $310.0M | $316.5M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B |
| Total Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B |